Cargando…
SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone
Background: Short stature is the most frequent clinical manifestation in Turner syndrome (TS), occurring in 98% of these patients. Growth hormone was shown to improve adult height in TS patients from diverse genetic backgrounds. However, there are few studies on adult height in TS patients from deve...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209222/ http://dx.doi.org/10.1210/jendso/bvaa046.1649 |
_version_ | 1783531025079468032 |
---|---|
author | Scalco, Renata Da Cunha Braz, Adriana Farrant Malaquias, Alexsandra C Antonini, Sonir Roberto Rauber Guerra-Junior, Gil Mendonca, Berenice Bilharinho Jorge, Alexander A L |
author_facet | Scalco, Renata Da Cunha Braz, Adriana Farrant Malaquias, Alexsandra C Antonini, Sonir Roberto Rauber Guerra-Junior, Gil Mendonca, Berenice Bilharinho Jorge, Alexander A L |
author_sort | Scalco, Renata Da Cunha |
collection | PubMed |
description | Background: Short stature is the most frequent clinical manifestation in Turner syndrome (TS), occurring in 98% of these patients. Growth hormone was shown to improve adult height in TS patients from diverse genetic backgrounds. However, there are few studies on adult height in TS patients from developing countries, where the diagnosis is frequently delayed. Objective: To compare adult height between GH-treated and untreated TS patients. Patients and methods: 120 GH-treated and 109 GH-untreated TS patients from 3 referral hospitals in Brazil were evaluated. The most common reasons for not treating TS patients with GH were late diagnosis or GH unavailability. Data on karyotype, parents’ height, puberty development and GH treatment were obtained from their medical records. Adult height was determined when growth velocity was inferior to 1cm/year during a minimum follow-up period of 12 months. Results: The frequency of 45,X karyotype was similar between the groups (48.7% vs. 41.9% in GH-treated vs. GH-untreated TS patients, respectively, P= 0.639). GH-treated TS patients started GH therapy at a chronological age (CA) of 11.2 ± 3.7 yr, bone age of 9.3 ± 3.1 yr, height SDS (British 1965 standards) -3.1 ± 1.1. GH mean dose was 48µg/kg.d and GH treatment duration was 5.4 ± 3.0 yr. Estrogen replacement was started late, at CA of 14.3 ± 2.0 yr in GH-treated and at 14.9 ± 1.9 yr in GH-untreated patients, and the rate of spontaneous puberty was similar between the groups (GH-treated 16.8% vs. GH-untreated 22,8%, P=0.304). Adult height was significantly higher after GH treatment (150.1 ± 5.8 cm vs. 143.3 ± 7.2 cm in GH-treated vs. untreated TS patients, respectively, P < 0.001), even with a small but significant difference in target height between the groups (158.2 ± 4.8 vs. 159.8± 4.5 cm in GH-treated vs. untreated TS patients, respectively, P= 0.015). More than half of the TS GH-treated patients reached normal adult height (equal or higher than 150.2 cm), whereas only 15.6% of GH-untreated patients reached it. Conclusion: Despite the delayed diagnosis of TS patients in our cohort, GH treatment was associated with a significant height gain, and the TS GH-treated group was around 7 cm taller than the GH-untreated group. |
format | Online Article Text |
id | pubmed-7209222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72092222020-05-13 SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone Scalco, Renata Da Cunha Braz, Adriana Farrant Malaquias, Alexsandra C Antonini, Sonir Roberto Rauber Guerra-Junior, Gil Mendonca, Berenice Bilharinho Jorge, Alexander A L J Endocr Soc Pediatric Endocrinology Background: Short stature is the most frequent clinical manifestation in Turner syndrome (TS), occurring in 98% of these patients. Growth hormone was shown to improve adult height in TS patients from diverse genetic backgrounds. However, there are few studies on adult height in TS patients from developing countries, where the diagnosis is frequently delayed. Objective: To compare adult height between GH-treated and untreated TS patients. Patients and methods: 120 GH-treated and 109 GH-untreated TS patients from 3 referral hospitals in Brazil were evaluated. The most common reasons for not treating TS patients with GH were late diagnosis or GH unavailability. Data on karyotype, parents’ height, puberty development and GH treatment were obtained from their medical records. Adult height was determined when growth velocity was inferior to 1cm/year during a minimum follow-up period of 12 months. Results: The frequency of 45,X karyotype was similar between the groups (48.7% vs. 41.9% in GH-treated vs. GH-untreated TS patients, respectively, P= 0.639). GH-treated TS patients started GH therapy at a chronological age (CA) of 11.2 ± 3.7 yr, bone age of 9.3 ± 3.1 yr, height SDS (British 1965 standards) -3.1 ± 1.1. GH mean dose was 48µg/kg.d and GH treatment duration was 5.4 ± 3.0 yr. Estrogen replacement was started late, at CA of 14.3 ± 2.0 yr in GH-treated and at 14.9 ± 1.9 yr in GH-untreated patients, and the rate of spontaneous puberty was similar between the groups (GH-treated 16.8% vs. GH-untreated 22,8%, P=0.304). Adult height was significantly higher after GH treatment (150.1 ± 5.8 cm vs. 143.3 ± 7.2 cm in GH-treated vs. untreated TS patients, respectively, P < 0.001), even with a small but significant difference in target height between the groups (158.2 ± 4.8 vs. 159.8± 4.5 cm in GH-treated vs. untreated TS patients, respectively, P= 0.015). More than half of the TS GH-treated patients reached normal adult height (equal or higher than 150.2 cm), whereas only 15.6% of GH-untreated patients reached it. Conclusion: Despite the delayed diagnosis of TS patients in our cohort, GH treatment was associated with a significant height gain, and the TS GH-treated group was around 7 cm taller than the GH-untreated group. Oxford University Press 2020-05-08 /pmc/articles/PMC7209222/ http://dx.doi.org/10.1210/jendso/bvaa046.1649 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Pediatric Endocrinology Scalco, Renata Da Cunha Braz, Adriana Farrant Malaquias, Alexsandra C Antonini, Sonir Roberto Rauber Guerra-Junior, Gil Mendonca, Berenice Bilharinho Jorge, Alexander A L SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title | SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title_full | SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title_fullStr | SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title_full_unstemmed | SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title_short | SAT-107 Improved Adult Height in Brazilian Turner Syndrome Patients Treated with Growth Hormone |
title_sort | sat-107 improved adult height in brazilian turner syndrome patients treated with growth hormone |
topic | Pediatric Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209222/ http://dx.doi.org/10.1210/jendso/bvaa046.1649 |
work_keys_str_mv | AT scalcorenatadacunha sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT brazadrianafarrant sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT malaquiasalexsandrac sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT antoninisonirrobertorauber sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT guerrajuniorgil sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT mendoncaberenicebilharinho sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone AT jorgealexanderal sat107improvedadultheightinbrazilianturnersyndromepatientstreatedwithgrowthhormone |